A clinical reality affecting tens of millions of men worldwide, recognised in modern medicine as a treatable condition rather than a personal failing. The shift in framing — from the older “impotence” framing carrying psychosocial-stigma to the contemporary “erectile dysfunction” framing as routine medical diagnosis — represents one of the more substantive vocabulary-and-clinical-practice transitions in male sexual medicine across the late 20th century.

Erectile dysfunction (Japanese: 勃起障害, bokki-shōgai; English: erectile dysfunction, ED; older term: impotence) is defined as “the persistent or recurrent inability to attain, or to maintain until completion of sexual activity, an adequate erection” (NIH Consensus Statement, 1992). The condition was historically referred to as impotence, but the term was deemed to carry pejorative connotations and was replaced by erectile dysfunction in clinical vocabulary.

Distinction in vocabulary

The English vocabulary for the condition has undergone substantial register-shift across the 20th century. Impotence operated as the standard clinical-and-everyday term through the 1980s, with the term carrying psychosocial-stigma connotations of “absence of male potency” extending beyond the strictly-physical erectile function. The 1992 NIH Consensus Conference’s adoption of erectile dysfunction (ED) as the formal clinical term, together with the 1998 sildenafil approval and the subsequent direct-to-consumer pharmaceutical advertising, drove the clinical and everyday vocabulary shift from impotence to ED.

The Japanese vocabulary parallels this trajectory: inpotentsu (インポテンツ, German-derived) and the everyday inpo (インポ) operated as the older terms, with bokki-shōgai (勃起障害, “erection disorder”) and bokki-fuzen (勃起不全, “erection inadequacy”) as the contemporary clinical replacements. The 1998 sildenafil approval and subsequent direct-to-consumer awareness expansion drove the Japanese vocabulary-shift on a similar timeline.

Both English and Japanese formal-clinical registers now treat ED as the standard, with impotence / inpo surviving only in residual everyday or historical contexts. The shift is one of the more visible recent vocabulary changes in sexual medicine.

Epidemiology

The Massachusetts Male Aging Study (MMAS), a major epidemiological investigation, found some degree of ED affecting approximately 52% of men aged 40-70, with prevalence rising with age. The study established the broad-population baseline for ED epidemiology and remains widely-cited reference for the population-level scale of the condition.

In Japan, the 1998 approval of sildenafil (Viagra) drove rapid public-awareness expansion of ED. Japanese Society for Sexual Medicine surveys estimate approximately 11.3 million Japanese men age 40 and above with some degree of ED symptoms (2003 estimate), with only a small fraction of this estimated population receiving treatment. Japanese men show a particular reluctance to seek consultation, framing the issue as “embarrassing” or “age-related” — a low-consultation-rate pattern recognised as a clinical-and-public-health problem in the Japanese context.

Classification

ED is classified by aetiology into three main categories:

Organic ED (vascular-, neural-, or hormonal-cause ED): aetiologies include diabetes mellitus, hypertension, atherosclerosis, hyperlipidaemia, and obesity-induced arterial narrowing; post-prostate-surgery, pelvic-fracture, and other neural injuries; and testosterone deficiency producing hormonal ED.

Psychogenic ED: anxiety, depression, performance anxiety, partner-relationship difficulties, and similar psychological-factor-predominant cases. Tends to be more common in younger men, and the preservation of nocturnal penile tumescence (NPT) supports a psychogenic-predominant diagnosis.

Mixed ED: combination of organic and psychological factors. Most middle-aged and older ED falls in this category.

Diagnosis

History-taking uses the International Index of Erectile Function (IIEF) as the international standard tool. The 15-item instrument assesses erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.

Laboratory and instrumental tests include blood tests (glucose, lipids, testosterone), nocturnal penile tumescence monitoring (RigiScan), penile-artery ultrasonography, and others as clinically-indicated.

Treatment

PDE5 inhibitors (phosphodiesterase type 5 inhibitors) are the worldwide first-line treatment. The class enhances corpus-cavernosum nitric-oxide signalling by inhibiting cGMP degradation, promoting smooth-muscle relaxation and blood inflow. Representative drugs are sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). In Japan, low-dose daily tadalafil (5 mg) was approved in 2012 as an additional approach for continuous baseline erectile-function support.

For PDE5-inhibitor-non-responder cases, alternatives include intracavernosal injection therapy (alprostadil), vacuum erection device (VED), and surgical penile prosthesis implantation. The European Association of Urology (EAU) ED Guidelines and the American Urological Association (AUA) ED Guidelines provide concordant treatment-pathway frameworks across major Western medical jurisdictions.

For psychogenic ED, psychotherapy and sex counselling are effective, and combined PDE5-inhibitor-with-psychotherapy approaches are recommended for many presentations.

Lifestyle and prevention

ED is recognised as a risk marker for cardiovascular disease. Multiple research findings suggest that ED onset typically precedes myocardial-infarction or stroke onset by 2-5 years on average, framing ED as an early sign of vascular-endothelial dysfunction.

Smoking cessation, regular physical activity, weight management, and alcohol moderation are effective for the prevention-and-improvement of organic ED. Aerobic exercise specifically (150 minutes per week of moderate-intensity activity) has been shown in multiple meta-analyses to produce statistically-significant improvement in ED metrics.

Cultural shift in framing

The vocabulary-and-clinical-framing shift from impotence to erectile dysfunction parallels a broader cultural shift in the framing of male sexual function. The older impotence concept carried implicit framing of male sexual capacity as a holistic-personal-attribute, with the loss reading as a personal-deficiency. The contemporary ED framing treats the function as a routine medical-clinical category, with treatment as routine clinical practice.

The shift has reduced the stigma threshold for seeking clinical evaluation, particularly in Western contexts where direct-to-consumer pharmaceutical advertising has substantively-normalised ED-clinical-discussion. Japan’s lower consultation rate compared to Western jurisdictions suggests the framing-shift is incomplete in the Japanese context, with continued cultural-reluctance to discuss the condition as routine medical issue.

The contemporary clinical literature consistently frames ED as a treatable medical condition with substantial population-level prevalence, with the appropriate response framed as routine consultation-and-treatment rather than personal-failing-management.

Related Terms

• Erection (bokki)
• Sex hormones
• Prostate
• Libido
• Morning erection (asa-dachi)
• Male menopause (LOH)
• Couple sexuality